Back

Low dose of basiliximab for induction immunosuppresion therapy for heart transplant results in favourable outcomes

29 April 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Advanced heart failure Advance heart failure HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Doctor Veraprapas kittipibul

Duke University Health System, Durham (United States of America)

7 More presentations in this session

Presentation thumbnail
Influence of a continuous veno-venous hemofiltration on the long-term prognosis in patients with an advanced heart failure and an acute coronary syndrome
Doctor O. Trebacz (Krakow, PL)
Abstract
Presentation thumbnail
Beta-blockers uptitration between infusions predicts event-free survival in advanced heart failure treated with repeated cures of low-dose levosimendan
Doctor P. Yerly (Lausanne, CH)
Abstract
Presentation thumbnail
Utility of cTnT-hs and sAXL for prognosis evaluation after heart transplantation
Doctor S. Mirabet Perez (Barcelona, ES)
Abstract
Presentation thumbnail
Predictors of mortality at six months after in advanced heart failure patients attended in primary care
Doctor J. Verdu (Barcelona, ES)
Abstract
Presentation thumbnail
Intermitent treatment with levosimendan in outpatients with chronic advanced heart failure: our experience.
Doctor J. Garcia Pinilla (Malaga, ES)

Access the full session

Session thumbnail
Poster Session 1 - Advanced heart failure

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources